Abstract
Insomnia is frequently reported in children with autism spectrum disorder (ASD) and is associated with the severity of hyperactivity, irritability, sensory sensitivities, and related symptoms. The aim of this study was to examine the extent of healthcare utilization associated with insomnia in children with ASD. We conducted a retrospective, cross-sectional study of 541 children with ASD registered at the National Autism Database of Israel (NADI). Parents of all children completed the Children’s Sleep Habits Questionnaire (CSHQ) and insomnia was defined as a total CSHQ score ≥48. We compared sociodemographic characteristics, ASD diagnostic measures, chronic comorbidities, medication usage, hospitalizations, visits to the emergency room (ER), and visits to specialists between ASD children with and without insomnia. Finally, we assessed the independent association of insomnia with clinical characteristics and healthcare utilization using multivariate logistic regression models. Of the 541 children with ASD, 257 (47.5%) had insomnia. Children with insomnia compared to children without insomnia exhibited higher rates of comorbidities within the symptoms, signs, and ill-defined conditions (ICD-9[780–789]) category (aOR=1.70; 95%CI=1.04-2.77; p=0.033) and were prescribed more medications for chronic comorbidities (aOR=1.47; 95%CI=1.01-2.15; p=0.046). Finally, ASD children with insomnia were 1.75 and 2.82 times more likely to visit the ER and be hospitalized than their counterparts (aOR=1.75; 95%CI=1.17-2.62; p=0.007 and aOR=2.82; 95%CI=1.43-5.56; p=0.003, respectively). Our findings demonstrate that insomnia is associated with greater healthcare utilization among children with ASD. Thus, treating insomnia in children with ASD may have a broad clinical impact beyond specific improvements in sleep disturbances.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Neurim Pharmaceuticals Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Soroka University Medical Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
